COMPANY
Athna Biotech Inc.
Funding and NIH signals
- NIH award NIH awarded $937K (STTR Phase II 2R42CA262399-02, competing renewal, notice Sep 10, 2026); 2 NIH awards totaling $2.04M in the last 12 months. NIH RePORTER 2R42CA262399-02 (Sep 10, 2026)
Evidence (2 events)
- Sep 10, 2026 · NIH RePORTER 2R42CA262399-02
Organization: ATHNA BIOTECH, INC.; City/State: Athens, GA; Project number: 2R42CA262399-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 937492; Administering IC: National Cancer Institute; Project title: Development of a salt-based nanomedicine for non-muscle invasive bladder cancer; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 5R42CA257584-03
Organization: ATHNA BIOTECH, INC.; City/State: Athens, GA; Project number: 5R42CA257584-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1098560; Administering IC: National Cancer Institute; Project title: Development of a radiation-activatable nanoparticle for lung cancer therapy; Organization type: Domestic For-Profits
- Sep 10, 2026 · NIH RePORTER 2R42CA262399-02